Study of 111In-XYIMSR-01 SPECT/CT in Patients With Metastatic Clear Cell Renal Cell

Part of paid clinical trials in Baltimore, Maryland.

Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study ID
NCT07062549
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Renal Cell Carcinoma (Kidney Cancer)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • 111In-XYIMSR-01 — DRUG
    Unite Dose: 10.5±1 mCi of 111In-XYIMSR-01 Route of administration: Intravenous catheter placed in an antecubital vein or an equivalent venous access

Study Details

This study is being done to determine if the investigational radiotracer called 111In-XYIMSR-01 is helpful in detecting clear cell renal cell carcinoma tissue in your body when used during a SPECT-CT Scan

Key Dates

Start date
Jan 26, 2022
Status verified
Jul 2025
Primary completion
Jul 31, 2027
Completion
Jul 31, 2029

Study Design

Enrollment
6 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER

Arms

  • Experimental: A (111In-XYIMSR-01)
    Participants who receive 111In-XYIMSR-01 dosing and SPECT/CT imaging

Primary Outcome Measure

Number of adverse events [ Time Frame: From enrollment to the end of treatment at 1 week ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Johns Hopkins UniversityBaltimoreMaryland21287
Yasser Ged, MBBS
[email protected]
410-955-8893
Yasser Ged, MBBS (PRINCIPAL_INVESTIGATOR)

Find similar trials in Baltimore, MD

By research site
Johns Hopkins University· Baltimore, MD

Related Studies